AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease

AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to severe active Crohn's disease.